Log in

NASDAQ:ASND - Ascendis Pharma A/S Stock Price, Forecast & News

$130.25
-5.58 (-4.11 %)
(As of 02/26/2020 08:53 AM ET)
Today's Range
$128.85
Now: $130.25
$137.28
50-Day Range
$130.25
MA: $139.09
$145.11
52-Week Range
$68.41
Now: $130.25
$145.59
Volume106,859 shs
Average Volume106,511 shs
Market Capitalization$6.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.68
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.50 million
Book Value$7.87 per share

Profitability

Net Income$-153,650,000.00
Net Margins-789.80%

Miscellaneous

Employees216
Market Cap$6.22 billion
Next Earnings Date4/1/2020 (Estimated)
OptionableOptionable

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.


Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Tuesday, May, 23rd. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.19. The biotechnology company earned $0.40 million during the quarter, compared to the consensus estimate of $1.10 million. Ascendis Pharma A/S had a negative return on equity of 29.04% and a negative net margin of 789.80%. View Ascendis Pharma A/S's Earnings History.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, April 1st 2020. View Earnings Estimates for Ascendis Pharma A/S.

What price target have analysts set for ASND?

8 Wall Street analysts have issued 12 month price objectives for Ascendis Pharma A/S's stock. Their forecasts range from $139.00 to $186.00. On average, they expect Ascendis Pharma A/S's stock price to reach $158.00 in the next year. This suggests a possible upside of 21.3% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

What is the consensus analysts' recommendation for Ascendis Pharma A/S?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

Has Ascendis Pharma A/S been receiving favorable news coverage?

News articles about ASND stock have trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ascendis Pharma A/S earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Ascendis Pharma A/S.

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,430,000 shares, an increase of 12.5% from the January 15th total of 2,160,000 shares. Based on an average trading volume of 250,000 shares, the short-interest ratio is presently 9.7 days. Currently, 5.5% of the shares of the stock are short sold. View Ascendis Pharma A/S's Current Options Chain.

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the folowing people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)
  • Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (11.33%), RA Capital Management L.P. (9.93%), Artisan Partners Limited Partnership (5.12%), Farallon Capital Management LLC (3.04%), Westfield Capital Management Co. LP (2.99%) and Janus Henderson Group PLC (2.62%).

Which institutional investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Farallon Capital Management LLC, Franklin Resources Inc., Renaissance Technologies LLC, Lakewood Capital Management LP, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc. and FIL Ltd.

Which institutional investors are buying Ascendis Pharma A/S stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Westfield Capital Management Co. LP, Bank of New York Mellon Corp, Spyglass Capital Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., State Street Corp and RA Capital Management L.P..

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $130.25.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $6.22 billion and generates $12.50 million in revenue each year. The biotechnology company earns $-153,650,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.View Additional Information About Ascendis Pharma A/S.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is http://www.ascendispharma.com/.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: FTSE 100 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel